Association between β3-adrenergic receptor agonist use and risk of kidney cancer among patients with overactive bladder.

Jee Soo Park,Myung Eun Lee,Won Sik Jang,Jongchan Kim,Gwangmo Shin,Won Sik Ham

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.456

IF: 45.3

2024-02-01

Journal of Clinical Oncology

Abstract:456 Background: New aspects of β3-AR have been recently described with overexpression in cancers. Although post-authorization safety study of mirabegron, the first approved β3-AR agonist for overactive bladder (OAB), found no association between mirabegron use and risk of overall cancer, subgroup analysis revealed that some malignancies were significantly associated with β3-AR agonist use. This study aimed to examine whether cumulative β3-AR agonist use is associated with a higher risk of kidney cancer and demonstrate underlying mechanisms of β3-AR agonist through murine model. Methods: This nationwide population cohort study included newly diagnosed OAB patients who initiated their OAB medications between 2015 and 2020. In pulmonary metastatic orthotopic murine mRCC model, primary tumor weight and number of lung nodules were measured and evaluation of browning of perinephric fat (PF) and tumor immune microenvironment (TIME) was performed and compared between β3-AR agonist and vehicle treatment groups. Results: Among a total of 3,728,929 patients, 7,437 (0.2%) developed kidney cancer after starting OAB medications. There was an increased risk of kidney cancer among β3-AR agonist users (hazard ratio (HR)=1.514, 95% confidence interval (CI) 1.418–1.615) compared to anticholinergic users. The incidence of kidney cancer was also significantly increased with an increase in the cumulative dose of mirabegron (adjusted HR (aHR)=1.221 (1.104-1.351) for 30-180 cDDDs (cumulative defined daily doses), aHR=1.413 (1.281-1.558) for >181 cDDDs) compared to low-dose cDDDs (<30 cDDDs)). The β3-AR agonist treated mice demonstrated significantly higher primary tumor burden and lung metastasis with increased mitosis in cancer cells and browning of PF. Immunofluorescence analysis demonstrated that β3-AR agonist modulate TIME by increasing both myeloid-derived suppressor cells and regulatory T cells. Conclusions: This is the first study to demonstrate the association of kidney cancer and β3-AR agonist both in murine and human studies. By showing that the β3-AR agonist not only increases PF browning but also induces immune tolerance which eventually increases the initiation and progression of kidney cancer, we suggest β3-AR as the potential therapeutic target for novel anti-neoplastic approaches.

oncology